Moneycontrol
HomeNewsBusinessMoneycontrol ResearchSai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0
Trending Topics
Sensex Live
Pine Labs Share Price
Tenneco Clean Air India IPO
Groww IPO
Gold Rate

Sai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0

Anubhav Sahu   •

Globally, more than 50 percent of the research and development (R&D) spending is done in nine select pharma hubs, and, hence, it is rewarding to have a presence in these locations.

Anthem Biosciences will be the second CRDMO to debut on stock exchanges in less than a year.

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More